4 assets in Malignant Conjunctival Melanoma

Therapeutic assets addressing Malignant Conjunctival Melanoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Malignant Conjunctival Melanoma	H. Lee Moffitt Cancer Center and Research Institute	P1	CC (47)
Fludarabine Malignant Conjunctival Melanoma	H. Lee Moffitt Cancer Center and Research Institute	P1	CC (47)
Tbio-4101 Malignant Conjunctival Melanoma	H. Lee Moffitt Cancer Center and Research Institute	P1	CC (47)
Nivolumab Malignant Conjunctival Melanoma	Fred Hutchinson Cancer Center	P1	CC (43)